MAP2K1 and ovarian cancer: Similarly, it has been observed that a selective inhibitor of MEK1/2 (U0126), as well as siERK1/2, enhanced the OV433 ovarian cancer cell sensitivity to cisplatin, which were otherwise resistant to this drug, during 24 hours of treatment [14].